People want drug industry oversight

Share this article:
US adults want information on and oversight of the drug industry, according to a recent Harris Poll. Poll officials said 71% of adults surveyed believe it is very important or highly important that marketed drugs remain under close review by the FDA and drug companies. Only 9% of respondents said such review is only somewhat or not very important.

The researchers said many Americans are demonstrating consumerism by seeking information on drug safety, with 41% of those surveyed saying they always or often seek information on drug safety for themselves or family members.

Another 35% said they sometimes seek drug safety information, while only 24% said they rarely or never look for safety information.

There were age differences in the responses, with those who are older more likely to be concerned about drug safety.

“The public's desire for drug safety information and their belief that drugs should remain under continued review by FDA and drug companies indicates that Americans may have concerns regarding the full safety profile of all drugs,” the pollsters said. “These questions on safety may be negatively affecting their impressions of the industry…Ultimately, the findings continue to highlight the need for drug companies to build and maintain consumer confidence as a key component of their overall corporate reputation.”

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...